Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 7
Submit an article Journal homepage
2,165
Views
46
CrossRef citations to date
0
Altmetric
Original Research

PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma

Chang-Long ChenCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China
,
Qiu-Zhong PanDepartment of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
Jing-Jing ZhaoDepartment of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
Ying WangDepartment of Epidemiology and Health Statistics, Guangdong Key Laboratory of Molecular Epidemiology, Guangdong Pharmaceutical University, Guangzhou, China
,
Yong-Qiang LiDepartment of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
Qi-Jing WangDepartment of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
Ke PanCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China;Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
De-Sheng WengCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China;Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
Shan-Shan JiangCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China
,
Yan TangCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China;Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
,
Xiao-Fei ZhangCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China
,
Hong-Xia ZhangCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China
,
Zi-Qi ZhouCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China
,
Yi-Xin ZengCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China;Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China
&
Jian-Chuan XiaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China;Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaCorrespondence[email protected]
 show all
Article: e1176653 | Received 09 Oct 2015, Accepted 04 Apr 2016, Published online: 29 Jun 2016

Citations (46)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Yun Zhou, Chang-long Chen, Sen-wei Jiang, Yanling Feng, Linjing Yuan, Ping Chen, Lan Zhang, Shuting Huang, Jundong Li, Jian-Chuan Xia & Min Zheng. (2019) Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. OncoImmunology 8:2.
Read now
Albert J. Czaja. (2018) Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Review of Gastroenterology & Hepatology 12:6, pages 547-564.
Read now
Jian Zhang, Huizhong Li, Dazhi Gao, Baofu Zhang, Maojin Zheng, Mingyin Lun, Mengxue Wei, Rui Duan, Maomao Guo, Jiajun Hua, Qian Liu, Jin Bai, Hui Liu, Junnian Zheng & Hong Yao. (2018) A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biology & Therapy 19:6, pages 475-483.
Read now
Kunlin Xie, Lin Xu, Hao Wu, Haotian Liao, Lin Luo, Mingheng Liao, Jianping Gong, Yang Deng, Kefei Yuan, Hong Wu & Yong Zeng. (2018) OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis. OncoImmunology 7:4.
Read now
Carole Fournier, François Martin, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Lionel Apetoh. (2017) Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology 6:11.
Read now
Yiming Meng, Zhifu Yu, Yefeng Wu, Tianzhao Du, Shi Chen, Fanjuan Meng, Nan Su, Yushu Ma, Xiaoxi Li, Sulan Sun & Guirong Zhang. (2017) Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application. Human Vaccines & Immunotherapeutics 13:6, pages 1379-1387.
Read now

Articles from other publishers (40)

Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli & Claudio Tiribelli. (2023) PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma. International Journal of Molecular Sciences 24:17, pages 13357.
Crossref
Chae Eun Lee, Jeong Hwan Lee, Hyun Joo Chung, Da Won Lee, Jong Seok Lim, Kibum Kim, Jin Wook Kim, Yong Seong Lee, Kyung Soo Kim, Hyun Jin Min, Kisung Ko & Soon Chul Myung. (2023) Expression and in vitro function of anti-PD-L1 human antibody expressed in plant. Plant Biotechnology Reports 17:4, pages 531-539.
Crossref
Hongjie Xin, Qianwei Lai, Yuchen Zhou, Jian He, Yangda Song, Minjun Liao, Jiarun Sun, Meng Li, Mingxia Zhang, Weifang Liang, Yang Bai, Yongyuan Zhang & Yuanping Zhou. (2023) Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma. Frontiers in Immunology 14.
Crossref
Xue-Qin Gong, Ning Liu, Yun-Yun Tao, Li Li, Zu-Mao Li, Lin Yang & Xiao-Ming Zhang. (2023) Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma. Scientific Reports 13:1.
Crossref
Xiaoqiang Gao & Shi Zuo. (2023) Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. Clinical and Experimental Medicine.
Crossref
Xiaoqiang Yin, Tongchui Wu, Yadong Lan & Wulin Yang. (2022) Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Bioscience Reports 42:2.
Crossref
Caecilia H C Sukowati, Korri Elvanita El-Khobar & Claudio Tiribelli. (2021) Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells 13:7, pages 795-824.
Crossref
Wei Jiang, Tao Li, Jiaojiao Guo, Jingjing Wang, Lizhou Jia, Xiao shi, Tingting Yang, Ruonan Jiao, Xin Wei, Zhenqing Feng, Qi Tang & Guozhong Ji. (2021) Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Li-Li Liu, Shi-Wen Zhang, Xue Chao, Chun-Hua Wang, Xia Yang, Xin-Ke Zhang, Yan-lin Wen, Jing-Ping Yun & Rong-Zhen Luo. (2020) Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunology, Immunotherapy 70:2, pages 417-429.
Crossref
Guosheng Yuan, Yangda Song, Qi Li, Xiaoyun Hu, Mengya Zang, Wencong Dai, Xiao Cheng, Wei Huang, Wenxuan Yu, Mian Chen, Yabing Guo, Qifan Zhang & Jinzhang Chen. (2021) Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Frontiers in Immunology 11.
Crossref
Svetlana Bornschlegl, Michael P Gustafson, Danae A Delivanis, Mabel Ryder, Minetta C Liu, George Vasmatzis, Chris L Hallemeier, Sean S Park, Lewis R Roberts, Ian F Parney, Diane F Jelinek & Allan B Dietz. (2021) Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. Clinical & Translational Immunology 10:4.
Crossref
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki & Ebrahim Faghihloo. (2020) The roles of programmed death ligand 1 in virus-associated cancers. Infection, Genetics and Evolution 84, pages 104368.
Crossref
Xing Huang, Xiaozhen Zhang, Jian Xu, Xun Wang, Gang Zhang, Tianyu Tang, Xiaochao Shen, Tingbo Liang & Xueli Bai. (2020) Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. Frontiers in Oncology 10.
Crossref
Jin-Zhi Zhang, Yu-Zhu Ma, Jia-Lin Gu & Jie-Ge Huo. (2020) Clinical research progress of immune checkpoint inhibitors in treatment of primary liver cancer. World Chinese Journal of Digestology 28:14, pages 605-616.
Crossref
Xing Huang, Xiaozhen Zhang, Xueli Bai & Tingbo Liang. (2019) Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. Cellular & Molecular Immunology 17:7, pages 677-679.
Crossref
Sukeshi Patel Arora, Gabor Liposits, Susan Caird, Richard F. Dunne, Gordon Taylor Moffat, David Okonji, Maria Grazia Rodriquenz, Divyanshu Dua & Efrat Dotan. (2020) Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. Journal of Geriatric Oncology 11:4, pages 557-565.
Crossref
Xiao-Song Li, Jun-Wei Li, Hui Li & Tao Jiang. (2020) Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Bioscience Reports 40:4.
Crossref
Ji Hye Kim, Kyungbin Kim, Misung Kim, Young Min Kim, Jae Hee Suh, Hee Jeong Cha & Hye Jeong Choi. (2020) Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer. Journal of Pathology and Translational Medicine 54:2, pages 154-164.
Crossref
Zi-Qi Zhou, Jing-Jing Zhao, Qiu-Zhong Pan, Chang-Long Chen, Yuan Liu, Yan Tang, Qian Zhu, De-Sheng Weng & Jian-Chuan Xia. (2019) PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Yanhui Chen, Quanxing Liu, Zhiming Chen, Yating Wang, Wanning Yang, Ying Hu, Wenbo Han, Hui Zeng, Haitao Ma, Jigang Dai & Henghui Zhang. (2019) PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Gao-Min Liu, Xu-Gang Li & Yao-Min Zhang. (2019) Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell International 19:1.
Crossref
Hye Won Lee, Kyung Joo Cho, Soon Young Shin, Ha Yan Kim, Eun Ju Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn & Kwang-Hyub Han. (2019) Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. Journal of Liver Cancer 19:2, pages 108-116.
Crossref
Mengxin Tian, Yinghong Shi, Weiren Liu & Jia Fan. (2019) Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Science China Life Sciences 62:9, pages 1138-1143.
Crossref
Jing Cao, Fan-Hua Kong, Xi Liu & Xiao-Bo Wang. (2019) Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World Journal of Gastroenterology 25:27, pages 3649-3663.
Crossref
T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora & D. C. Leucuta. (2018) Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clinical and Translational Oncology 21:6, pages 702-712.
Crossref
Shixia Bu, Boning Li, Qian Wang, Tingting Gu, Qianggang Dong, Xiaofei Miao & Dongmei Lai. (2019) Epithelial ovarian cancer stem‑like cells are resistant to the cellular lysis of cytokine‑induced killer cells via HIF1A‑mediated downregulation of ICAM‑1. International Journal of Oncology.
Crossref
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano & Isabelle Dussault. (2019) Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Medicine 6.
Crossref
Xingliang Guo, Hua Jiang, Bizhi Shi, Min Zhou, Honghong Zhang, Zhimin Shi, Guoxiu Du, Hong Luo, Xiuqi Wu, Yi Wang, Ruixin Sun & Zonghai Li. (2018) Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Frontiers in Pharmacology 9.
Crossref
Jing-Hua Li, Wei-Jie Ma, Gang-Gang Wang, Xiang Jiang, Xi Chen, Long Wu, Zhi-Su Liu, Xian-Tao Zeng, Fu-Ling Zhou & Yu-Feng Yuan. (2018) Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis. Frontiers in Immunology 9.
Crossref
Boyang Chang, Lujun Shen, Kefeng Wang, Jietian Jin, Tao Huang, Qifeng Chen, Wang Li & Peihong Wu. (2018) High number of PD ‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients . Liver International 38:8, pages 1449-1458.
Crossref
Ritu Shrestha, Prashanth Prithviraj, Matthew Anaka, Kim R. Bridle, Darrell H. G. Crawford, Bijay Dhungel, Jason C. Steel & Aparna Jayachandran. (2018) Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Frontiers in Oncology 8.
Crossref
Albert J. Czaja. (2018) Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. Digestive Diseases and Sciences 63:7, pages 1706-1725.
Crossref
Yating Tang, Guang Li, Shan Wu, Lingrong Tang, Ning Zhang, Jinzhao Liu, Shuo Zhang & Lei Yao. (2018) Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. Oncology Letters.
Crossref
Janis M Taube, Jérôme Galon, Lynette M Sholl, Scott J Rodig, Tricia R Cottrell, Nicolas A Giraldo, Alexander S Baras, Sanjay S Patel, Robert A Anders, David L Rimm & Ashley Cimino-Mathews. (2017) Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology 31:2, pages 214-234.
Crossref
Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand & Anja Katrin Bosserhoff. (2017) Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option. Oncotarget 9:3, pages 3605-3618.
Crossref
Li-Wei Liu, Ming-Ya Yang, Min Zhou, Jia-Jia Li, Bo Liu & Yue-Yin Pan. (2017) Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. Cancer Biomarkers 20:4, pages 609-615.
Crossref
Chun-yu Huang, Ying Wang, Guang-yu Luo, Feng Han, Yong-qiang Li, Zhong-guo Zhou & Guo-liang Xu. (2017) Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Journal of Immunotherapy 40:9, pages 323-333.
Crossref
Elisa Cappuzzello, Roberta Sommaggio, Paola Zanovello & Antonio Rosato. (2017) Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine & Growth Factor Reviews 36, pages 99-105.
Crossref
Yu-Feng Yang, Ying-Hua Pan, Yun Cao, Jia Fu, Xia Yang, Mei-Fang Zhang & Qiu-Hong Tian. (2017) PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma. Oncotarget 8:29, pages 47195-47205.
Crossref
Mohammad Reza Zamani, Saeed Aslani, Arash Salmaninejad, Mohammad Reza Javan & Nima Rezaei. (2016) PD-1/PD-L and autoimmunity: A growing relationship. Cellular Immunology 310, pages 27-41.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.